



MODIGENE TO PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE

Nes-Ziona, Israel September 15, 2008 -- Modigene Inc. (OTCBB: MODG), a biopharmaceutical company applying its patented technology to develop longer-acting versions of already approved therapeutic proteins, today announced that President Shai Novik will present at the upcoming UBS Global Life Sciences Conference at 2:00 PM EDT on September 24, 2008.

The audio portion of the company's presentation will be webcast live. It can be accessed at the Investors section of the Modigene website at www.modigeneinc.com. An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation.

For more information about the UBS 2008 Global Life Sciences Conference, visit www.ibb.ubs.com.

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

MODIGENE CONTACT:
Shai Novik, President
Modigene Inc.
Tel: +1 866 644-7811
Email: shai@modigeneinc.com

MEDIA CONTACT:
Barbara Lindheim
GendeLLindheim BioCom Partners
+1 212 918-4650